FGF/FGFR signaling systems provide diverse mechanistic targets across multiple systemic autoimmune rheumatic diseases
New research maps potential targets for several autoimmune diseases
This evidence-informed review synthesizes the role of FGF/FGFR signaling in conditions including Rheumatoid Arthritis, SLE, and SSc-ILD. The…
Researchers are mapping out how specific proteins might help manage conditions like rheumatoid arthritis and lupus by targeting tissue repai…
Belimumab plus standard therapy shows numerically greater reductions in IgA, IgM, and anti-dsDNA antibodies
Trial Shows Belimumab May Help Manage Lupus Nephritis Symptoms
This Phase 3 randomized controlled trial of 446 adults with active lupus nephritis found that intravenous belimumab plus standard therapy re…
A Phase 3 trial identifies specific markers that may help predict how patients with lupus nephritis respond to belimumab treatment.
STAT3 inhibition targets cytokine signaling and renal inflammation in systemic lupus erythematosus and lupus nephritis
New review suggests STAT3 inhibition could help lupus kidney disease
This narrative review examines the role of STAT3 in systemic lupus erythematosus and lupus nephritis. The authors argue that STAT3 integrate…
A narrative review suggests targeting STAT3 might treat lupus kidney inflammation, though direct drug targeting remains unproven in patients…
Tubulointerstitial inflammation and fibrosis predict renal function decline in adult lupus nephritis patients across multiple studies
Kidney damage in lupus is linked to specific tissue changes seen in scans
A systematic review of 3,607 adult patients reveals that tubulointerstitial inflammation and fibrosis significantly increase the risk of ren…
A large review found that kidney tissue changes called tubulointerstitial inflammation and fibrosis raise the risk of kidney failure in lupu…
Commentary on plateau in lupus nephritis trials and path to precision medicine
New lupus drugs hit a ceiling where kidney healing stops improving
This commentary reviews 200 interventional pharmacological trials in lupus nephritis. The authors note a persistent ceiling effect with comp…
Kidney healing in lupus patients using new drugs often stops improving after reaching a 40 to 50 percent success rate, limiting how much bet…
Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
Genetic marker may lower risk of cyclophosphamide toxicity in lupus patients
This meta-analysis of 5 observational studies found that the CYP2C19*2 genetic polymorphism is associated with a protective effect against…
A genetic variant linked to lower risk of cyclophosphamide side effects in lupus patients, though evidence remains limited by small study si…
Systematic Review Links Lysosomal Pathways to Autoimmune Kidney Disease Progression
Lysosomal pathways may control autoimmune kidney disease progression
This systematic review synthesizes evidence that lysosomal functions act as checkpoints in autoimmune kidney diseases like lupus nephritis a…
New evidence suggests that targeting lysosomal functions could offer a new way to manage serious autoimmune kidney diseases.
Mini Review Covers Complement Pathways in Kidney Diseases and Injuries
Review offers overview of kidney disease treatments and risks
This mini review examines the role of complement-mediated mechanisms across multiple renal pathologies without specific outcome data.
This mini review summarizes current knowledge on kidney conditions like lupus nephritis and transplant care, offering a broad look at the fi…
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Retrospective Analysis of Repeat Kidney Biopsy Outcomes in 19 Pediatric Lupus Nephritis Patients
Small study examines repeat kidney biopsies in children with lupus nephritis
This retrospective cohort study evaluated 19 pediatric lupus nephritis patients aged 5 to 18 years at Nanjing Children's Hospital between 20…
A small study of 19 children with lupus nephritis shows how repeat kidney biopsies track disease changes over time to guide future treatment…
LOC100130476 rs80213143 variant associated with SLE susceptibility and renal involvement in Chinese Han cohort
Genetic variant linked to lupus susceptibility and kidney involvement in Chinese study
A cohort study in a Chinese Han population found the rs80213143 variant at LOC100130476 was associated with systemic lupus erythematosus sus…
A specific genetic marker found in Chinese patients is strongly linked to lupus and predicts more severe kidney disease.
Research across Systemic Lupus Erythematosus
Related studies from across the Systemic Lupus Erythematosus family.
Genistein shows potential to attenuate inflammation and reduce disease severity in autoimmune conditions
Genistein may help reduce inflammation in several autoimmune diseases
This mini review synthesizes preclinical evidence on genistein for autoimmune diseases including SLE, RA, and type 1 diabetes. Findings sugg…
A review of genistein shows it could lower disease severity and inflammation for people with conditions like lupus and rheumatoid arthritis.
Belimumab linked to higher remission and low disease activity rates in SLE without glucocorticoids
Trial shows belimumab improves remission rates for lupus patients
A post hoc analysis of phase III trials found that belimumab plus standard therapy led to higher rates of DORIS remission and LLDAS attainme…
A new analysis of clinical trials shows that the drug belimumab helps more people with lupus reach specific remission goals compared to a pl…
Deucravacitinib modulates up to 2529 genes and SLE-relevant gene sets including interferon-regulated genes
Trial Shows Deucravacitinib Modulates Gene Activity in Lupus Patients
This post hoc analysis of a Phase 2 trial in 363 patients with systemic lupus erythematosus (SLE) found that deucravacitinib modulated up to…
A Phase 2 trial shows that deucravacitinib may influence specific gene sets and immune cell activity in people with systemic lupus erythemat…
Corticosteroid and cyclophosphamide exposure are associated with higher mortality in Middle Eastern and North African SLE
Specific Medications Linked to Survival Rates in Lupus Patients
This meta-analysis of 3,478 adult patients in the MENA region found an all-cause mortality rate of 9.9% (95% CI: 7.2%-14.0%). While corticos…
New data identifies how specific medications and health conditions impact long-term survival for patients with systemic lupus erythematosus.
Anti-DFS70 antibodies show high specificity but low sensitivity for excluding Systemic Lupus Erythematosus
Anti-DFS70 Antibodies May Help Rule Out Systemic Lupus Erythematoma
This meta-analysis evaluates the diagnostic performance of anti-DFS70 antibodies in patients with Systemic Lupus Erythematoma (SLE). The ana…
A large analysis suggests that specific antibodies could help doctors rule out systemic lupus, though more research is needed to confirm the…
Aerobic and resistance exercise improve fatigue, physical function, and pain in systemic lupus erythematosus
Exercise Eases Fatigue and Pain in Lupus Patients
This meta-analysis of 470 adults with SLE found that aerobic, resistance, or combined exercise leads to small-to-moderate improvements in fa…
A review of 470 lupus patients finds exercise improves fatigue, pain, and mood without worsening disease activity.
Small PNH clones in SLE linked to thrombotic events and hemolysis in case series
Small blood cell issues can impact patients with lupus and PNH
A systematic review of 8 cases found that 37.5% of SLE patients with PNH had thrombotic events and 87.5% had detectable hemolysis. The findi…
A review of cases shows that even small clusters of abnormal cells can cause serious blood complications in people with lupus and PNH.
Dapirolizumab pegol increases BICLA response rate by 14.6% over placebo in moderate-to-severe SLE
Trial shows dapirolizumab pegol improves symptoms for lupus patients
This Phase 3 randomized controlled trial of 321 patients with moderate-to-severe, active SLE found that dapirolizumab pegol added to standar…
A new clinical trial found that dapirolizumab pegol significantly improved disease activity for adults with moderate to severe systemic lupu…
SLE patients have a 2- to 3-fold higher risk of intracerebral hemorrhage compared to non-SLE populations
Lupus Patients Face Higher Risk of Brain Bleeding
This literature review and case report analyze the association between systemic lupus erythematosus (SLE) and intracranial hemorrhage (ICH).…
Patients with systemic lupus erythematosus may face a much higher risk of brain bleeds compared to those without the condition.
Systemic immune-inflammation index and systemic inflammation response index correlate with disease activity in systemic lupus erythematosus
Inflammation markers are higher in lupus patients than in healthy people
This meta-analysis of eleven studies involving individuals with systemic lupus erythematosus and healthy controls examined inflammatory mark…
A new analysis shows inflammation markers are much higher in people with lupus. These markers also track closely with how active the disease…
Stress-induced IL-6 upregulation impairs skeletal growth and bone health in children with inflammatory diseases
Stress hormones may harm bone growth in children with inflammatory conditions
This narrative review synthesizes evidence from animal models and pediatric inflammatory disorders showing that stress-induced IL-6 upregula…
A review suggests stress-induced IL-6 upregulation impairs skeletal growth and bone health in kids with inflammatory disorders, highlighting…
Adrenal insufficiency is first manifestation in 73.6% of APS patients with adrenal involvement
Review finds adrenal crisis common in lupus and antiphospholipid syndrome cases
This systematic review and pooled individual-patient analysis of 155 published APS/SLE-spectrum patients with adrenal involvement found that…
A review of 155 patients shows adrenal crisis is frequent in lupus and antiphospholipid syndrome, highlighting the need for urgent care.
Questions about Lupus Nephritis
Do complement pathways cause kidney injuries in patients with lupus nephritis?
Yes, complement pathways — especially the classical and alternative pathways — contribute to kidney injury in lupus nephritis by driving inflammation and tissue damage after immune complex deposition.
Full answer →Is there a genetic variant linked to lupus nephritis risk in Chinese Han populations?
Yes, the rs80213143 variant in LOC100130476 is linked to lupus nephritis risk in Chinese Han populations, with the C allele associated with more severe kidney involvement.
Full answer →What role do lysosomal pathways play in the progression of autoimmune kidney disease like lupus nephritis?
Lysosomal pathways act as checkpoints that regulate immune activation, autoantigen processing, and metabolic-immune crosstalk, driving lupus nephritis progression.
Full answer →Does having the CYP2C19*2 gene variant protect against cyclophosphamide side effects in lupus nephritis?
Yes, the CYP2C19*2 variant is linked to reduced cyclophosphamide toxicity in lupus nephritis, based on a meta-analysis showing a protective effect.
Full answer →How does belimumab compare to anifrolumab for treating lupus nephritis?
Belimumab is approved for lupus nephritis and appears more effective than anifrolumab, which is not yet approved for this condition.
Full answer →All Lupus Nephritis Articles
- FGF/FGFR signaling systems provide diverse mechanistic targets across multiple systemic autoimmune rheumatic diseases
- Belimumab plus standard therapy shows numerically greater reductions in IgA, IgM, and anti-dsDNA antibodies
- STAT3 inhibition targets cytokine signaling and renal inflammation in systemic lupus erythematosus and lupus nephritis
- Tubulointerstitial inflammation and fibrosis predict renal function decline in adult lupus nephritis patients across multiple studies
- Commentary on plateau in lupus nephritis trials and path to precision medicine
- Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
- Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
- Systematic Review Links Lysosomal Pathways to Autoimmune Kidney Disease Progression
- Mini Review Covers Complement Pathways in Kidney Diseases and Injuries
- Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
- Retrospective Analysis of Repeat Kidney Biopsy Outcomes in 19 Pediatric Lupus Nephritis Patients
- LOC100130476 rs80213143 variant associated with SLE susceptibility and renal involvement in Chinese Han cohort
- Review examines glucose metabolic reprogramming in SLE and lupus nephritis pathogenesis
- Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation